Small molecules or kinase inhibitors targeting growth factor receptors and the PI3K/AKT/mTOR, Src/Stat, p38, and ATM/CHK2 pathways were extensively investigated for cancer treatment, both preclinically and clinically, including treatment for lung cancers [29]–[31]. This evidence concerns the gene SRC and lung carcinoma.